I12 | Macro Paper Warehouse

Germs in the Family: The Short- and Long-Term Consequences of Intra-Household Disease Spread

Mon, 01 Jan 0001 00:00:00 +0000

This paper studies the short- and long-term consequences of intra-household respiratory disease transmission from older to younger siblings in Danish families. The central research questions are: (1) how do respiratory illnesses spread from preschool-aged older siblings to younger infant siblings during the first year of life, and (2) how does respiratory disease exposure during infancy causally affect younger siblings’ long-term economic, human capital, and health outcomes?

The study uses population-level Danish administrative data covering 1,230,180 children from 37 birth cohorts (1981–2017), linking records from the National Patient Register, income and labor market registers, education registers, and psychiatric care registers. The identification strategy combines birth order variation in respiratory disease vulnerability with within-municipality variation in local respiratory disease prevalence among children aged 13–71 months. The authors construct a municipality-level disease exposure index—cumulative respiratory hospitalizations per 100 children aged 13–71 months in a child’s municipality over their first 12 months of life—and estimate the differential effect of this index on younger versus older siblings, controlling for municipality fixed effects, birth year-month fixed effects, and an extensive set of individual and family background characteristics.

The descriptive findings are stark: younger siblings have 2–3 times higher rates of hospitalization for acute respiratory conditions during their first year of life compared to older siblings at the same age, with the gap largest at ages two and three months. The gap is larger for winter births, shorter birth spacing, and when older siblings attend childcare centers—all patterns consistent with the older sibling serving as a disease vector.

On the causal estimates, moving from the 25th to the 75th percentile of the disease exposure index distribution increases the younger sibling’s acute respiratory hospitalizations in the first year of life by 0.023 (32.9 percent above the sample mean), with effects more than twice as large for exposure in the first six months compared to the second six months.

In the long run, an interquartile increase in first-year respiratory disease exposure reduces younger siblings’ wage earnings (conditional on employment) at ages 25–32 by 0.8 percent and total income by 0.8 percent, and reduces their income percentile rank by 0.3 percentage points. There is no significant effect on labor force participation at the extensive margin. Effects on earnings are approximately twice as large when exposure is measured in the first six months of life. These earnings effects are comparable in magnitude to those from a 10 percent reduction in birth weight or a 9 percent increase in ambient air pollution at birth, and correspond to roughly two-thirds of the adult earnings impact of in utero exposure to the 1918 Spanish Influenza. When the disease index interaction is included, the main birth order coefficient declines by approximately 70 percent, suggesting intra-household disease transmission is an important channel underlying the documented birth order earnings disadvantage.

Additional findings include: a 0.5 percentage point reduction in high school graduation and a 0.6 percentage point reduction in college graduation (interquartile effects); a 0.01 standard deviation penalty in ninth grade Danish test scores; a 20 percent increase (0.016 per hundred per year) in chronic respiratory hospitalizations at ages 16–26; and a 6.1 percent increase (0.5 additional visits per hundred per year) in psychiatric clinic visits at ages 16–26. Breastfeeding mitigates short-term effects, with 15 months of breastfeeding sufficient to entirely offset the elevated hospitalization risk.

Scope conditions: findings apply to second-born relative to first-born children in Danish sibling pairs with at least 11 months birth spacing; long-term estimates are net of parental compensatory responses and any immunity benefits, and thus represent lower bounds of the uncompensated biological impact of respiratory illness in infancy.

Q: What is the magnitude of the birth order gap in acute respiratory hospitalizations during infancy, and what patterns support an intra-household transmission mechanism? A: Younger siblings have 2–3 times higher hospitalization rates for acute respiratory conditions in the first year of life compared to older siblings at the same age, with the gap especially large at ages two and three months. The gap is larger for winter births (when respiratory viruses circulate more), for siblings with shorter birth spacing, and when the older sibling attends a childcare center. Hospitalizations for non-infectious digestive diseases and injuries show no analogous birth order differences, ruling out differential parental healthcare-seeking as an explanation.

Q: How is the disease exposure index constructed and what variation does it exploit? A: The index is the cumulative count of acute respiratory hospitalizations per 100 children aged 13–71 months in a child’s municipality over their first 12 months of life, with the older sibling excluded from the count when applicable. It exploits irregular spatial and temporal waves of respiratory viruses (such as RSV and influenza) across Danish municipalities. The interquartile range of this index captures meaningful variation in community disease burden faced by infants across different places and years.

Q: What is the first-stage relationship between the disease index and infant hospitalizations? A: Moving from the 25th to the 75th percentile of the disease index increases younger siblings’ acute respiratory hospitalizations in the first year of life by 0.023 (a 32.9 percent increase relative to the sample mean), while the effect on older siblings is substantially smaller. The interaction coefficient in the preferred specification implies that one additional hospitalization per 100 community children aged 13–71 months raises the younger sibling’s hospitalization count by 0.012 more than the older sibling’s. Effects are more than twice as large for exposure in the first compared to the second six months of life.

Q: What are the estimated long-term effects on adult earnings, and how do they compare to benchmarks in the literature? A: An interquartile increase in first-year respiratory disease exposure reduces younger siblings’ wage earnings at ages 25–32 by 0.8 percent and total income by 0.8 percent, with a 0.3 percentage point reduction in income percentile rank. These magnitudes are comparable to a 1 percent earnings reduction from a 10 percent birth weight reduction (Black et al., 2007), a 1 percent earnings reduction from a 9 percent increase in ambient air pollution (Isen et al., 2017b), and roughly two-thirds of the in utero Spanish Influenza effect (Almond, 2006).

Q: Does the birth order earnings disadvantage reflect intra-household disease transmission? A: When the interaction between birth order and the disease index is excluded, the regression finds a 1.9 percent birth order earnings disadvantage for second-born children (consistent with Black et al., 2005 range of 1.2–4.2 percent). When the interaction is included, the main birth order coefficient declines by approximately 70 percent, suggesting that disease transmission from older to younger siblings is an important channel driving the birth order earnings penalty.

Q: Are effects larger for exposure in the first versus second six months of life? A: Yes, consistently across all outcomes. The interaction coefficient for acute respiratory hospitalizations is more than twice as large when exposure is measured in the first versus second six months. Effects on wage earnings are approximately 60 percent larger for first-half exposure, and effects on income rank are two to three times larger. This is consistent with biomedical evidence that infants’ immune systems mature around six months when solid food introduction begins.

Q: What are the effects on educational outcomes? A: An interquartile increase in first-year respiratory disease exposure reduces the likelihood of high school graduation by 0.5 percentage points (0.6 percent at the sample mean) and college graduation by 0.6 percentage points (1.7 percent at the sample mean), with effects approximately 60 percent larger when measuring first-half exposure. A 0.01 standard deviation reduction in ninth grade Danish test scores is also found. A back-of-the-envelope calculation using Danish returns to schooling suggests the reduction in educational attainment can explain approximately half of the estimated earnings effect.

Q: What are the effects on chronic respiratory and mental health outcomes? A: An interquartile increase in first-year exposure increases chronic respiratory hospitalizations (asthma, COPD) at ages 16–26 by 0.016 per hundred per year (20 percent above the sample mean), with significant increases also apparent at ages one to two. For mental health, the same exposure is associated with 0.5 additional psychiatric clinic visits per hundred per year at ages 16–26 (6.1 percent above the sample mean), with effects becoming more significant in the early twenties. Effects on mental health from this paper are smaller than those estimated for more extreme fetal and early childhood shocks such as Ramadan exposure or maternal bereavement.

Q: What does the acute respiratory trajectory look like beyond infancy? A: Elevated acute respiratory hospitalizations persist at age one, then there is a reduction at ages two to three consistent with an immunity formation hypothesis, but this protective effect disappears by age four. There is no significant increase or decrease in acute respiratory hospitalizations at older ages, in contrast to the persistent increase found for chronic respiratory conditions.

Q: What heterogeneity is found in short-term effects? A: Effects on infant respiratory hospitalizations are larger for low birth weight children, for male infants (consistent with the fragile male hypothesis), for siblings with shorter birth spacing, and for sibling pairs where the older child attends childcare. The monotonic decline in effect size with increasing birth spacing is the opposite of what would be predicted if differential parental time investment were the main mechanism, supporting intra-household disease spread as the operative channel.

Q: What is the role of breastfeeding as a moderator? A: Using supplementary data on breastfeeding duration (covering 2009–2016, matched to 7.6 percent of the sample), the authors find that the impact of disease exposure on younger siblings’ infancy hospitalizations declines significantly with longer breastfeeding duration. A linear specification implies that 15 months of breastfeeding entirely offsets the elevated hospitalization risk from higher disease exposure. Second-born children breastfed for less than half a month are particularly vulnerable to acute respiratory infections.

Q: How do the authors validate the identifying assumption? A: Three validation exercises are used. First, results are robust to adding municipality-specific linear and quadratic trends and maternal fixed effects. Second, using family background characteristics as outcomes in the interaction regression, at most two of fourteen coefficients are significant in any specification, and all effect sizes are less than one percent of sample means. Third, using alternative disease indices based on non-infectious digestive diseases and injuries shows no differential effects for younger siblings, ruling out a parental healthcare-seeking confound.

Q: What are the policy implications? A: The authors highlight breastfeeding support policies (paid family leave, workplace lactation accommodations), RSV vaccination campaigns for pregnant women and monoclonal antibody prophylaxis for infants, sick pay regulations, and childcare attendance policies as levers to reduce infant respiratory disease burden. They argue that current cost-benefit evaluations of such policies likely undercount the long-term human capital and earnings benefits. The COVID-19 pandemic illustrates the mechanism: restrictions reduced RSV spread during 2020 potentially benefiting infants with older siblings, while the subsequent RSV surge in 2021–2022 may have exposed later cohorts to above-average disease burden.

Respiratory Disease Exposure Index: A municipality-level cumulative measure of acute respiratory hospitalizations per 100 children aged 13–71 months assigned to each child over their first 12 months of life (or first and second six months separately), designed to proxy for community respiratory disease burden faced by infants from slightly older children, with the child’s own older sibling excluded from the count.

Intra-Household Disease Transmission: The mechanism by which preschool-aged older siblings, exposed to respiratory viruses in group childcare settings, bring home those viruses and infect younger infant siblings who are in a vulnerable stage of immune and brain development, creating a within-family externality in health outcomes.

Differential Birth Order Effect (Identification): The quasi-experimental design exploits the interaction between birth order (younger siblings are more exposed to older siblings’ illnesses) and local disease prevalence variation to identify causal impacts, netting out the main effects of both birth order and local disease environment through municipality and birth year-month fixed effects.

Immunity Formation Hypothesis: The conjecture that early respiratory disease exposure may have a protective effect on later acute respiratory illness through immune system training; supported in the data by reduced acute hospitalizations at ages two to three, though this protection disappears by age four and does not prevent chronic respiratory disease development.

Dynamic Complementarities with Sibling Health Spillovers: An extension of the Cunha-Heckman framework: while standard models incorporate investment complementarities across time periods for a given child, this paper’s findings imply that sibling health spillovers create differential returns to early-life health investments by birth order, since disease asymmetries between older and younger siblings are not incorporated in existing theoretical models.

Net Long-Term Effects: The estimated long-run impacts incorporate not only the direct biological effects of respiratory illness on the younger sibling but also any parental compensatory responses and immunity benefits; thus they represent lower bounds of the uncompensated biological impact, as parental compensation would attenuate the measured sibling difference.

Republican Support and Economic Hardship: The Enduring Effects of the Opioid Epidemic

Mon, 01 Jan 0001 00:00:00 +0000

This paper establishes a causal connection between the opioid epidemic and the political realignment toward the Republican Party in the United States from the mid-2000s through 2022. The authors—Carolina Arteaga and Victoria Barone—exploit rich geographic variation in Purdue Pharma’s initial marketing strategy for OxyContin, drawn from unsealed litigation records, to construct a quasi-exogenous measure of community-level exposure to the epidemic.

The identification strategy rests on a documented feature of OxyContin’s 1996 launch: Purdue initially targeted the established cancer pain market—physicians and patients already using MS Contin—as an entry point into the much larger noncancer pain market. Areas with higher cancer mortality in 1996 received disproportionate pharmaceutical marketing, leading to outsized opioid prescription growth that spilled over from cancer patients to the broader population through shared physicians. The authors use 1996 commuting-zone (CZ) cancer mortality rates as a proxy for this initial targeting, interacted with year fixed effects in an event-study specification with CZ and state-year fixed effects. The sample covers 625 CZs across the continental United States from 1982 to 2022.

The empirical chain runs through three stages. First, the instrument strongly predicts opioid supply: by 2012, a one-standard-deviation higher 1996 cancer mortality rate led to an additional 0.97 opioid doses prescribed per capita, 65% above the baseline mean. Second, the resulting epidemic caused measurable mortality and economic hardship. A one-standard-deviation increase in 1996 cancer mortality caused drug-induced deaths in 2017 to be 46% above the pre-epidemic average; by 2012 the same increase caused prescription opioid deaths to be 61% higher. Excess mortality was concentrated among individuals under age 55, with no significant effects for those aged 55 and older. The epidemic also raised disability applications: SSDI applications rose by 12% and SSI applications by 7.6% by 2012, effects that persisted through 2020. SNAP enrollment in exposed CZs was 8% higher by 2022, equivalent to a 0.14 standard deviation increase.

Third, and centrally, the communities that endured these health and economic shocks shifted persistently toward the Republican Party. By the 2022 House elections, a one-standard-deviation increase in 1996 cancer mortality increased the Republican two-party vote share by 4.5 percentage points. Effects of similar magnitude appear in presidential elections (4.6 percentage points) and gubernatorial elections (4.3 percentage points). The vote-share shift is consistent across gender, age, race, and education, with no detectable change in voter turnout. The shift translates into actual seat gains: beginning in 2012, exposed areas consistently elected more Republican House members, moving the chamber’s roll-call voting in a more conservative direction. The effect is not driven by anti-incumbent sentiment—results hold regardless of which party held the seat at the time.

The paper identifies three reinforcing mechanisms. First, the Republican Party repositioned itself during this period as the advocate of “forgotten America” and working-class economic hardship, a message that resonated acutely in opioid-devastated communities. Second, conservative-leaning newspapers covered the epidemic at higher rates, and their coverage tracked local mortality; liberal-leaning outlets showed no such correlation. Fox News covered opioid stories at 1.5 times the rate of CNN and 1.7 times the rate of MSNBC, emphasizing crime, trafficking, and cartels at twice the frequency of liberal outlets. Third, exposed communities expressed stronger preferences for Republican-favored policy responses: higher police presence, greater sense of safety around law enforcement, and lower support for marijuana legalization on state ballot initiatives.

Pre-trend tests show no relationship between 1996 cancer mortality and outcomes before OxyContin’s launch. Out-of-sample exercises using 1976 cancer mortality find no analogous pattern in the pre-epidemic period (1982–1994). Placebo instruments based on unrelated causes of death yield null results. The baseline findings are robust to controlling for the China import shock, NAFTA, the 1994 Republican Revolution, the 2001 and 2008–2009 recessions, declining unionization, robot adoption, Fox News introduction, deaths of despair, and Southern and rural political realignment.

Q: What is the paper’s central research question? A: The paper asks whether the opioid epidemic causally increased Republican vote share in communities most severely affected by the crisis. It documents a causal chain from pharmaceutical marketing through drug mortality and economic hardship to political realignment, contributing the first causal estimate of a major public health crisis’s effect on partisan voting.

Q: What is the identification strategy, and why is 1996 cancer mortality a valid instrument? A: Purdue Pharma explicitly targeted physicians in the cancer pain market at OxyContin’s 1996 launch, then used those established relationships to expand into the noncancer pain market. CZs with higher cancer mortality in 1996 received disproportionate marketing, generating differential opioid prescription growth unrelated to pre-existing political or economic trends. Pre-trend tests confirm no differential patterns before 1996, out-of-sample tests using 1976 cancer mortality find no relationship with pre-epidemic outcomes, and placebos using unrelated causes of death yield null results.

Q: How strong is the first stage linking 1996 cancer mortality to opioid prescriptions? A: The relationship between 1996 cancer mortality and opioid prescriptions is positive and statistically significant from 1998 through 2020. By 2012—the year prescription rates peaked nationally at 81.3 per 100 persons—a one-standard-deviation higher cancer mortality rate led to an additional 0.97 morphine-equivalent doses prescribed per capita, 65% above the baseline mean. CZs in the highest cancer mortality quartile experienced a 1,800% increase in grams of oxycodone per capita between 1997 and 2010, compared to less than half that in the lowest quartile.

Q: What are the effects on drug-induced mortality? A: Drug-induced mortality (a broad measure covering deaths from prescription opioids, heroin, and fentanyl) rose continuously in exposed CZs after 1996. By 2017, a one-standard-deviation increase in 1996 cancer mortality caused drug-induced deaths to be 46% above the pre-epidemic average. By 2012, the same increase caused prescription opioid deaths specifically to be 61% higher relative to the pre-epidemic average. Excess mortality was concentrated among individuals under age 55, with no statistically significant effects for those aged 55 and older.

Q: What are the effects on disability program take-up? A: Applications for Social Security Disability Insurance (SSDI) rose by 12% and Supplemental Security Income (SSI) applications rose by 7.6% by 2012 for a one-standard-deviation increase in 1996 cancer mortality. These effects persisted: SSDI recipients grew by 15% and SSI recipients by 3.2% by 2020 in similarly exposed CZs. The increases in disability were concentrated among individuals under age 55, paralleling the mortality effects.

Q: What are the effects on SNAP enrollment? A: Exposed CZs showed a continuous increase in SNAP enrollment over two decades following the epidemic’s onset. By 2020, a one-standard-deviation increase in 1996 cancer mortality corresponded to an 8% increase in the share of the population receiving SNAP benefits, equivalent to 0.14 standard deviations. By 2022, the corresponding figure remains 8%, indicating persistent economic strain in exposed communities.

Q: What is the magnitude of the political effects in House elections? A: A one-unit increase in the 1996 cancer mortality rate yielded a 7.9-percentage-point increase in the 2022 Republican House vote share relative to 1996. Scaled to one standard deviation (0.58 units), this corresponds to a 4.5-percentage-point increase in the Republican two-party vote share by the 2022 midterms. The vote-share shift became statistically significant beginning in 2006, but only translated into consistent seat-level Republican gains starting in 2012.

Q: When did opioid exposure start winning Republicans additional House seats? A: Although the Republican vote share in exposed areas began increasing around 2006, actual seat flips did not become consistent until 2012. The paper explains this lag by noting that initial vote-share gains were concentrated in communities with low baseline Republican support, where additional votes did not immediately cross the winning threshold. Starting in 2010, median-baseline-Republican CZs also began shifting, enabling additional seat changes.

Q: How large are the presidential and gubernatorial election effects? A: In presidential elections, a one-standard-deviation increase in 1996 cancer mortality raised the Republican vote share by 4.6 percentage points. In gubernatorial elections, the same increase raised the Republican vote share by 4.3 percentage points after approximately six election cycles (corresponding to 2017–2020). These effects are described as comparable in magnitude to the difference in Republican vote share between the top and bottom quartiles of NAFTA vulnerability.

Q: Does the political shift reflect increased polarization toward extremist candidates? A: No. The paper finds no increase in the probability of electing candidates at the extremes of the Nokken-Poole ideological scale in any given election year. The ideological shift in the House composition arises from changes in which party wins seats rather than from the election of more extreme Republicans. Campaign donations to Republican candidates did not increase; rather, donations to Democratic candidates declined (in 2016, a one-standard-deviation increase in cancer mortality widened the Republican-Democrat donation gap by 0.44 standard deviations). The shift is interpreted as a change in voting preferences in previously Democratic-leaning areas, not heightened polarization.

Q: Is the shift driven by anti-incumbent sentiment? A: The authors test this by splitting the sample by the incumbent’s party at the time of each election and by redefining the outcome as the incumbent’s vote share. Neither exercise produces evidence of a systematic anti-incumbent response. The changes in Republican vote share are not statistically distinguishable based on whether the incumbent was a Republican or Democrat. If anything, after 2016 there is a slight increase in the likelihood of incumbents retaining their seats.

Q: Where geographically are the Republican gains largest? A: Using state-level treatment effects estimated from an in-differences model interacting cancer mortality with state-year indicators, the paper finds a strong positive correlation between the magnitude of the epidemic’s effect on economic hardship (measured by SNAP participation) and the magnitude of the Republican vote-share increase. This correlation is strongest with a lag: SNAP effects measured in 2006 are most predictive of vote-share shifts in 2022, indicating that deterioration in community economic fabric preceded and predicted the political realignment.

Q: How did conservative and liberal media differ in covering the opioid epidemic? A: Republican-leaning local newspapers covered the opioid epidemic more extensively than Democratic-leaning papers throughout the epidemic period, and their coverage tracked local opioid mortality rates; Democratic-leaning coverage showed no such correlation with local incidence. Fox News covered opioid stories at 1.5 times the rate of CNN and 1.7 times the rate of MSNBC. In terms of content, Republican-leaning newspapers showed 23% higher frequency of economic hardship keywords, 19% higher frequency of illegal activity and crime keywords, and 22% higher frequency of rehabilitation and treatment keywords relative to Democratic-leaning papers. Fox News emphasized crime, drug trafficking, and cartels at double the frequency of more liberal outlets.

Q: How did voter policy preferences align with Republican versus Democratic platforms? A: Using 2020 CCES data, the authors find that higher 1996 cancer mortality predicts a greater expressed preference for increasing the number of police officers on the street and a greater reported sense of safety around law enforcement—both consistent with the Republican Party’s law enforcement approach. Conversely, exposure to the epidemic predicts lower support for marijuana legalization on state ballot initiatives across 18 states from 2012 to 2023, indicating opposition to a key Democratic harm-reduction policy.

Q: What role did political actors themselves play in driving the realignment? A: Relatively little. The opioid epidemic was largely absent from House floor speeches until 2015 and from campaign advertising until 2020. Neither party took a clear legislative lead on the issue during the first two decades of the crisis. The authors interpret the political realignment as driven primarily by the Republican Party’s broader repositioning as the champion of working-class economic hardship and by differential media framing, rather than by active legislative competition over opioid policy.

Q: What major confounds are ruled out? A: The authors control for exposure to the China import shock, NAFTA, the 1994 Republican Revolution, the 2001 and 2008–2009 recessions, declining unionization, robot adoption, Fox News entry, deaths of despair (which include but are not limited to opioid deaths), and the political realignment of the South, rural areas, evangelicals, and the population over 65. Results remain robust across all these specifications. Placebo instruments using unrelated causes of death yield null results.

Q: Could the vote-share effects be mechanically driven by opioid-related deaths removing Democratic voters from the electorate? A: The authors perform a back-of-the-envelope calculation and estimate that even if all opioid-related deaths would have been Democratic votes, the mechanical effect on the Republican vote share is at most 0.22 percentage points relative to the observed 2020 vote share—far smaller than the estimated 4.5-percentage-point shift by 2022. The result is also inconsistent with a turnout mechanism, as voter turnout shows no meaningful change with epidemic exposure.

Opioid epidemic exposure instrument: The paper measures community-level exposure to the opioid epidemic using cancer mortality rates in 1996, the year OxyContin launched. This instrument is grounded in Purdue Pharma’s documented marketing strategy of targeting the cancer pain market first; areas with more cancer patients received disproportionate pharmaceutical marketing, generating differential opioid prescription growth that extended well beyond cancer patients to the broader noncancer population through shared physicians.

Commuting zone (CZ): The paper’s unit of geographic analysis, defined to capture local economic markets. There are 720 CZs in the US, encompassing all metropolitan and nonmetropolitan areas. The authors use 625 CZs with more than 20,000 residents, which account for more than 99% of all opioid deaths and total population.

Two-party Republican vote share: The ratio of votes for Republican candidates to the total votes for both Republican and Democratic candidates in a given election. The paper tracks this measure for House, presidential, and gubernatorial elections from 1976 or 1982 through 2020 or 2022, depending on data availability.

Drug-induced mortality: The paper’s broadest mortality measure, covering deaths from poisoning and medical conditions caused by legal or illegal drugs, including prescription opioids, heroin, and synthetic opioids such as fentanyl. It is distinguished from the narrower measures of prescription opioid deaths and all opioid deaths.

Issue ownership: The political science concept, used in the paper to describe how the Republican Party repositioned itself during the epidemic period as the voice of working-class economic hardship, “forgotten America,” and “America left behind.” The paper contrasts this with Democratic ownership of income inequality and argues that Republican ownership of the hardship narrative made the party’s message especially salient in heavily opioid-affected communities.

Path dependency in pharmaceutical marketing: Purdue’s strategy of concentrating initial OxyContin promotion in cancer-market areas, then later focusing on top-prescribing physicians (the highest three deciles of the distribution), meant that areas receiving high initial cancer-market promotion continued to receive disproportionate promotion as the company expanded to the noncancer market. This created a persistent targeting advantage for high-cancer CZs throughout the epidemic’s first wave.

Nokken-Poole ideological measure: A roll-call-based measure of elected House members’ ideology along the liberal-conservative dimension. The paper uses this measure to show that the epidemic shifted the composition of the House toward more conservative members, not by electing more extreme candidates in any given election, but by changing which party won seats over time.

The Effect of Provider Diversity on Racial Health Disparities: Evidence from the Military

Mon, 01 Jan 0001 00:00:00 +0000

This paper asks whether racial concordance between patients and medical providers — specifically, whether Black patients are treated by Black physicians — improves use of preventive care and reduces mortality among patients with chronic, manageable diseases. The authors argue that trust and communication deficits along racial lines cause Black patients to underuse low-cost, life-saving preventive care, and that increasing the share of Black providers addresses this deficit.

The authors use data from the Military Health System (MHS) Data Repository covering fiscal years 2003–2013, encompassing roughly 9.6 million beneficiaries. A distinctive feature of the MHS is that active-duty providers are themselves MHS beneficiaries, so their race is observed in the same eligibility files used for patients — overcoming the typical absence of provider-race data in claims databases. The study focuses on four chronic, deadly but manageable conditions: diabetes, hypertension, hypercholesterolemia, and clinical atherosclerotic cardiovascular disease. Preventive care is measured by medication fill-days for condition-appropriate generic drugs, HEDIS-recommended Comprehensive Diabetes Care compliance, and (for a subset) blood pressure control. Mortality is tracked across the full sample period.

The identification strategy exploits quasi-random variation in provider racial composition induced by across-base moves. The MHS setting generates abundant moves driven by DoD personnel management needs — not by patient health or preferences. Using a movers-only differences specification (analogous to Finkelstein et al. 2016), the authors compare differential changes in outcomes for Black versus non-Black patients who move to bases with larger versus smaller increases in the share of Black providers. This design includes fixed effects for both sending and receiving bases, controlling flexibly for regional quality differences. The estimand is an intent-to-treat effect among patients living within 10 miles of a base (who use on-base care 66% of the time).

The findings are consistent across all four disease samples. For diabetes, a move-induced one-standard-deviation increase in the share of Black diabetes providers is associated with a roughly 6 additional metformin fill-days per year (approximately 16% relative to the mean) and a 3 percentage-point increase (roughly 8% relative to the mean) in Comprehensive Diabetes Care compliance for Black relative to non-Black patients. Mortality falls by 0.4 percentage points — a 33% relative decline — for Black relative to non-Black diabetes patients following such a move.

Pooling across all four chronic-disease samples, a one-standard-deviation move-induced increase in the Black provider share is associated with approximately 3 additional fill-days of relevant preventive medication and a roughly 0.2 percentage-point reduction in mortality — approximately 15% relative to the mean mortality rate — for Black relative to non-Black patients.

A decomposition analysis combining the paper’s estimates with medical-literature parameters on the mortality effects of preventive medications finds that between 55% and 69% of the concordance mortality effect across the four disease samples can be attributed to improved medication adherence alone, with the remainder attributed to other aspects of the provider-patient relationship (e.g., lifestyle effects, other preventive care).

Scope conditions: results are local to MHS movers, who are on average slightly younger and healthier than non-movers, potentially understating concordance benefits for the full population. The MHS covers over 3% of all Black U.S. residents, but beneficiaries may differ from the general population. The paper measures Black patient / Black provider concordance specifically; it does not establish a symmetric concordance effect for non-Black patients. The concordance effect estimated is relative — it captures how much Black patients benefit more than non-Black patients from moving to a higher Black-provider-share base. A system-wide spillover mechanism (non-Black providers improving care for Black patients when working alongside more Black providers) cannot be ruled out and would also be consistent with the core concordance motivation.

Q: What is the central research question and why is the MHS an advantageous setting? A: The paper asks whether racial concordance between providers and patients causes Black patients to use more preventive care and achieve better health outcomes, focusing on the trust and communication channel. The MHS is advantageous because active-duty providers are themselves MHS beneficiaries, making their race observable — a feature absent in most claims databases. Across-base moves are driven by DoD staffing needs rather than patient health or preferences, providing quasi-random variation in provider racial composition. The system offers complete claims data covering both on- and off-base care, allowing full mortality tracking.

Q: How does the empirical strategy address selection concerns that plague prior concordance studies? A: Prior studies face selection problems from Black patients choosing different doctors than white patients and from residential segregation concentrating Black patients and Black physicians in regions with distinct care quality. The movers-based differences specification directly addresses both problems: it uses only patients who move across bases, comparing how the same individual’s outcomes change relative to non-Black patients experiencing the same move, as a function of the move-induced change in the Black provider share. Inclusion of fixed effects for both sending and receiving bases accounts flexibly for regional quality differences. Balance tests on observable patient characteristics show no differential sorting of Black versus non-Black patients toward high-Black-provider-share bases.

Q: What specific preventive care and outcome measures are used for each disease? A: For diabetes, the primary measures are annual metformin fill-days and Comprehensive Diabetes Care (CDC) compliance — defined as receiving HbA1c testing, a retinal eye exam, and medical attention for nephropathy in the focal year — plus blood pressure control (available only from 2009 onward for on-base patients). For hypertension, the measures are annual fill-days of WHO-recommended antihypertensives (thiazides, ACEs/ARBs, or long-acting dihydropyridine CCBs) and blood pressure control. For hypercholesterolemia, the measure is fill-days of antilipemic agents, bile acid sequestrants, and statins. For atherosclerotic cardiovascular disease, the HEDIS statin therapy receipt indicator is used. Mortality is tracked across all four samples.

Q: What are the main quantitative results for the diabetes sample? A: A move-induced one-standard-deviation increase in the share of Black diabetes providers is associated with approximately 6 additional metformin fill-days annually for Black relative to non-Black patients (roughly 16% relative to the mean). Compliance with Comprehensive Diabetes Care increases by 3 percentage points for Black relative to non-Black patients (roughly 8% relative to the mean). Mortality falls by 0.4 percentage points for Black relative to non-Black patients — a 33% relative decline — in connection with the same one-standard-deviation increase in Black provider share.

Q: What are the pooled results across all four chronic-disease samples? A: Pooling across diabetes, hypertension, hypercholesterolemia, and atherosclerotic cardiovascular disease, a one-standard-deviation move-induced increase in the Black provider share is associated with approximately 3 additional preventive medication fill-days per year for Black relative to non-Black patients. The pooled mortality effect is a 0.2 percentage-point reduction — roughly 15% relative to the mean mortality rate — for Black relative to non-Black patients.

Q: How much of the concordance mortality effect operates through medication adherence? A: The decomposition combines the paper’s estimated concordance effects on medication fill-days with medical-literature estimates of the mortality impact of each additional fill-day. For the diabetes sample, increased metformin adherence (4.2 additional fill-days) explains approximately 58.8% of the 0.4 percentage-point concordance mortality effect, with the residual 41.2% attributed to other channels such as lifestyle changes or other preventive care. Across all four disease samples, the medication fill-day channel explains between 55% and 69% of the respective concordance mortality effects.

Q: What specification checks do the authors conduct to validate causal identification? A: The authors conduct five main checks. First, balance regressions show that move-induced changes in Black provider share are not differentially related to baseline patient characteristics for Black versus non-Black patients. Second, regressions of the probability of moving on initial Black provider share and its interaction with patient race yield a near-zero concordance coefficient (0.008, SE 0.023), indicating no differential sorting. Third, regressions of post-move on-base care share on the concordance interaction term yield a near-zero coefficient (0.002, SE 0.003), indicating no differential race-specific selection into on-base care. Fourth, a distance falsification test shows that concordance coefficients are near zero and statistically insignificant for patients living more than 10 miles from the base. Fifth, event-study dynamics show no pre-move divergence in preventive care adherence between Black and non-Black patients, with a positive divergence emerging only after the move to a higher Black-provider-share base.

Q: How does the paper separate a concordance effect from a pure Black-physician-quality effect? A: The paper estimates a “first stage” specification on the subsample receiving on-base care (where provider race is observed), regressing the change in the probability of visiting a Black provider on the move-induced change in Black provider density. The results show an approximately one-to-one relationship between higher Black provider availability and increased visits to Black providers for all patients, with only a modest differential by patient race. This confirms that non-Black patients also see more Black providers when Black provider density rises, allowing the interaction specification to isolate concordance from a pure physician-quality effect.

Q: How do the authors assess the potential role of spillover effects? A: The authors acknowledge they cannot rule out that some of the estimated concordance effect arises through system-wide spillovers — for instance, non-Black providers on bases with more Black colleagues may improve their care for Black patients through peer learning or information transmission. They note that even if such a spillover mechanism operates, it is still consistent with the paper’s core concordance motivation, because provider-knowledge deficiencies about treating Black patients are among the theorized channels of racial discordance.

Q: What do the results imply for the overall racial mortality gap? A: Among MHS beneficiaries aged 20–65, Black beneficiaries are roughly 38% more likely to have diabetes and die over the sample period than non-Black beneficiaries; this gap appears driven primarily by higher diabetes prevalence rather than a within-diabetes mortality gap. Applying the diabetes concordance mortality estimate (a 0.4 percentage-point reduction), the authors calculate that a one-standard-deviation increase in the Black provider share would reduce the overall diabetes mortality gap from 38% to approximately 21% — a substantial narrowing driven by the concordance effect operating through conditional-on-prevalence outcomes.

Q: What are the policy implications of the findings? A: The results imply that investments in increasing physician workforce diversity could meaningfully reduce racial mortality disparities in the United States, particularly for chronic diseases manageable through preventive medication. The paper notes the results are relevant to affirmative action policies in medical school admissions, specifically the pending Supreme Court cases Students for Fair Admissions v. University of North Carolina and Students for Fair Admissions v. Harvard at the time of writing. The MHS population covered in the study includes over 3% of all Black U.S. residents, so the policy stakes extend substantially beyond the military context.

Q: What are the limitations of the study regarding generalizability? A: Movers in the chronic-disease samples are on average about four years younger and 0.2 percentage points less likely to die than non-movers, suggesting the local average treatment effect for movers may understate concordance benefits for the full population. The MHS population may be healthier overall than the general population, though conditioning on chronic-disease patients mitigates this concern. The paper covers only Black-patient/Black-provider concordance; concordance effects for other racial and ethnic groups are not estimated. The estimate of the concordance coefficient technically captures how much the Black patient / Black provider concordance effect exceeds the non-Black patient / non-Black provider concordance effect, meaning the absolute magnitude of Black concordance benefits is understated if non-Black concordance effects are also positive.

Racial concordance: In this paper’s usage, the match between the race of a patient and their treating physician — specifically Black patient / Black provider pairing — theorized to improve care through trust, communication, and reduced provider knowledge deficiencies about Black patients.

Provider Black share: The fraction of outpatient office visits for a given chronic condition at a given military base that are attended by Black active-duty providers, used as the base-level treatment variable; varies across bases from zero to approximately 20 percentage points in the pooled sample.

Movers-based differences specification: An identification strategy that restricts to patients who relocate across military bases exactly once during the sample period and estimates the differential change in outcomes for Black versus non-Black patients as a function of the move-induced change in the base’s Black provider share, including fixed effects for both the sending and receiving base.

Intent-to-treat (ITT) effect: The concordance estimate as applied to all patients living within 10 miles of a base — regardless of whether they actually received on-base care — to avoid selection bias from differential race-specific decisions to seek care on versus off base.

Comprehensive Diabetes Care (CDC): A HEDIS composite measure requiring receipt of all three of the following in the focal year: HbA1c testing, a retinal eye exam, and medical attention for nephropathy (via microalbumin exam, ACE/ARB therapy, or nephropathy treatment).

Medication fill-days: Annual days of supply dispensed for condition-appropriate generic medications (metformin for diabetes; thiazides/ACEs/ARBs/CCBs for hypertension; antilipemic agents, bile acid sequestrants, and statins for hypercholesterolemia; statins for atherosclerotic cardiovascular disease), used as the primary preventive care adherence measure.

Decomposition of concordance mortality effect: A calculation that uses the paper’s estimated concordance effect on medication fill-days, combined with medical-literature estimates of the mortality impact per fill-day, to determine what share of the total concordance mortality effect passes through medication adherence versus other channels (lifestyle, other preventive care).